NCT06387407View on ClinicalTrials.gov

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 10, 2025

Study Completion Date

November 25, 2025

Conditions

Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters

Interventions

DRUG

Dabigatran Etexilate 150mg

Oral dabigatran etexilate capsules, 150 mg twice a day.

All Listed Sponsors

lead

The Affiliated Hospital Of Guizhou Medical University

OTHER

NCT06387407 - Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran | Biotech Hunter | Biotech Hunter